Seres Therapeutics Inc. (MCRB) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

The market trend for Seres Therapeutics (MCRB), which specializes in combating intestinal pathogens, as shown on this price chart, demonstrates an EV/EBITDA of 0.00. The technical equipment of the plants is systematically updated, ensuring the uninterrupted packaging of medications. Its first-mover status in microbiome treatment guarantees physician trust. However, the slow implementation of new protocols and dependence on Nestlé Health create financial challenges until profitability is achieved.

Seres Therapeutics Inc. - MCRB Company Value to Operating Income Before Depreciation Ratio (period 11/23/2025 - 11/15/2026)

Summary analytical data breakdowns for Seres (MCRB)

- current price and projected stock value:

Stock Price serestherapeutics.com|MCRB - Analyst Median Target

- market capitalization details:

Market Value Seres|MCRB - Business Value

- book value of equity indicators:

Book Value per Share Seres Therapeutics|MCRB - Net Asset Value|Market Capitalization to Book Value Ratio serestherapeutics.com|MCRB - Company Assets

- company total debt and liquidity indicators:

- financial results and valuation multiples details:

MCRB - Company Profit|Expected Profit Seres Therapeutics|MCRB - Business Payback Period|Future Price to Earnings Seres Therapeutics Inc.|MCRB - Growth-Adjusted Market Cap to Net Income|EV/EBITDA Multiple Seres Therapeutics, Inc|MCRB - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Seres Therapeutics|MCRB - Earnings per share for the trailing year|Quarterly EPS earnings growth serestherapeutics.com|MCRB - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Seres Therapeutics

- sales volume and revenue information:

MCRB - Company Gross Revenue|Company Future Sales Volume Seres Therapeutics|MCRB - Market Capitalization-to-Revenue Ratio|Forward Price-to-Revenue Multiple Seres Therapeutics, Inc|MCRB - Revenue Change YoY (Last 12 Months)

General company analysis:serestherapeutics.com MCRB

Product sample of Seres Therapeutics Inc.

This indicator compares the total enterprise value, including net debt, with its operational profitability before taxes, depreciation, and amortization. Amid high competition in the microbiome therapy sector, such a metric reveals the real value of assets without accounting distortions. Analyzing the EV/EBITDA ratio of Seres Therapeutics (MCRB) allows for an assessment of the company's resilience to financial risks during the slow implementation of technologies. The price action on this chart serves as a filter to protect capital from overvalued debt obligations.

Analysis of competing companies

EV/EBITDA Multiple SMMT (summittxinc.com)|Total Company Value to Operating Income Before Depreciation Ratio modernatx.com (MRNA)|PCVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TARS (Tarsus Pharmaceuticals, Inc.) - Enterprise Value to Operating Income Before Depreciation|CRMD: EV/EBITDA Multiple|Company Value to Operating Income Before Depreciation Ratio SPRO (Spero)|SCYX (SCYNEXIS Inc) - EV/EBITDA Multiple|Company Value to EBITDA AN2 Therapeutics, Inc. ANTX|EV/EBITDA Multiple PYPD|Enterprise Value to Operating Income Before Depreciation Ratio LSB|Iterum Therapeutics - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation Ratio PHGE (BiomX Ltd)|Soligenix Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio 60 Degrees Pharmaceuticals, Inc. SXTP|oragenics.com (OGEN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA OpGen Inc (OPGN)